268
+1.52%
Close of 9 Nov 2026, in IDR
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Phapros Tbk PT
Its shares trade on IDX under the ticker PEHA.JK. It has been listed since 26 December 2018. In the fiscal year to 31 December 2025, it reported revenue of IDR 940.88bn and net income of IDR 28.03bn. At that date it held total assets of IDR 1.39trn and shareholders' equity of IDR 414.52bn.
PT Phapros Tbk is a pharmaceutical company, which engages in the production and marketing of pharmaceutical products. The company is headquartered in Jakarta Selatan, Dki Jakarta. The company went IPO on 2018-12-26. The firm's business pillars consist of branded/ethical prescription medicines: hospitals and pharmacies in addition to other healthcare institutions; over-the-counter drugs: pharmacies, retail; generic prescription drugs: government institutions and hospitals; toll-in manufacturing, and medical device. The company offers medicines for cardiovascular and hematopoietic, gastrointestinal and hepatobiliary, hormone Genito, urinary endocrine and metabolic, vitamins and minerals nutrition, dermatology, local anesthesia, immune & allergy, and others. The firm's medical devices include ACS MB system, ACS FB and FB PS, Primary Hip Stem, INASHUNT Semilunar Flushing, BoneFill Ortho and NPC-STRIP G. Its branded drugs include Colkatriol 0.25 mcg 30 Cap, Diafac XR, Diafac 500 mg 10 tablets, Spirolactone 25 & 1, Dextamine Syrup 60 ml, Diapros Tablet, Proinfarction, anemone, Pladel, and others. The firm also operates calibration laboratory.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Pharmaceuticals
- Listed since
- 26 Dec 2018
- Employees
- 1,494
- Website
- phapros.co.id ↗
Leadership
Pay as last reported
- Mr. Johanes Nanang MarjiantoPresident Commissioner
- Ms. Barokah Sri UtamiPresident Director
- Mr. Heru MarsonoDirector of Finance
- Ms. Chairani HarahapDirector of Marketing
- Mr. Fransetya Hasudungan HutabaratDirector of Human Resources and General
- Mr. Syamsul HudaDirector of Production
- Ms. Zahmilia AkbarCorporate Secretary
- Mr. Tumpal M. SihombingCorporate Secretary
- Drs. Masrizal Achmad SyariefCommissioner
- Mr. Zainal AbidinIndependent Commissioner
- Prof. Dr. Fasli JalalIndependent Commissioner
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 0
- Environment
- 0
- Social
- 0
- Governance
- 0
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Phapros Tbk PT has 1,494 employees in Jakarta Selatan, Indonesia.
- The company offers branded drugs like Colkatriol 0.25 mcg 30 Cap and Diafac XR.
- Phapros Tbk PT produces medical devices including ACS MB system and Primary Hip Stem.
Weaknesses
- Phapros Tbk PT's business is limited to Jakarta Selatan, Indonesia.
- The company's IPO was on 26 December 2018, which may limit growth.
- Phapros Tbk PT's products are focused on specific medical segments.
Opportunities
- Phapros Tbk PT can expand into over-the-counter drug markets in Indonesia.
- The company can leverage its toll-in manufacturing for new partnerships.
- Phapros Tbk PT can target government institutions for generic prescription drugs.
Threats
- Phapros Tbk PT faces competition from other pharmaceutical companies in Indonesia.
- The company's reliance on Jakarta Selatan may limit market reach.
- Phapros Tbk PT's business pillars may be affected by healthcare regulations.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.